Chenodeoxycholic acid
Names | |
---|---|
IUPAC name
3α,7α-Dihydroxy-5β-cholan-24-oic acid
| |
Systematic IUPAC name
(4R)-4-[(1R,3aS,3bR,4R,5aS,7R,9aS,9bS,11aR)-4,7-Dihydroxy-9a,11a-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid | |
Other names
Chenodiol
| |
Identifiers | |
3D model (
JSmol ) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard
|
100.006.803 |
EC Number |
|
IUPHAR/BPS |
|
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C24H40O4 | |
Molar mass | 392.57 g/mol |
Melting point | 165 to 167 °C (329 to 333 °F; 438 to 440 K) |
Pharmacology | |
A05AA01 (WHO) | |
License data | |
Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Chenodeoxycholic acid (CDCA; also known as chenodesoxycholic acid, chenocholic acid and 3α,7α-dihydroxy-5β-cholan-24-oic acid) is a bile acid. Salts of this carboxylic acid are called chenodeoxycholates. Chenodeoxycholic acid is one of the main bile acids.[1][2][3] It was first isolated from the bile of the domestic goose, which gives it the "cheno" portion of its name (Greek: χήν = goose).[4]
Structure
Chenodeoxycholic acid and cholic acid are the two primary bile acids in humans. Chenodeoxycholic acid has two hydroxyl groups and is modified with the addition of another hydroxyl group to produce cholic acid. Some other mammals have muricholic acid or deoxycholic acid rather than chenodeoxycholic acid.[1] It occurs as a white crystalline substance insoluble in water but soluble in alcohol and acetic acid, with melting point at 165–167 °C.[citation needed]
Biosynthesis and function
Chenodeoxycholic acid is synthesized in the
CDCA and other bile acids are
CDCA is the most potent natural bile acid at stimulating the nuclear bile acid receptor, farnesoid X receptor (FXR).[5] The transcription of many genes is activated by FXR, including those encoding FGF19 and small heterodimer partner.[6]
Therapeutic applications
Gallstones
CDCA has been used as medical therapy to dissolve gallstones.[7][8] Medical therapy with oral bile acids has been used in patients who have small cholesterol stones, and for patients with larger cholesterol gallstones who are unable or reluctant to have surgery. CDCA treatment can cause diarrhea, mild reversible hepatic injury, and a small increase in the plasma cholesterol level.[8]
Cerebrotendineous xanthomatosis
CDCA can be used in the treatment of cerebrotendineous xanthomatosis.[9]
Other
CDCA has been used in several other conditions.[10] As diarrhea is frequent when CDCA is used in gallstone dissolution, it has been studied as a possible treatment for constipation and has been shown to accelerate colonic transit and improve bowel function.[11]
The Australian biotechnology company Giaconda has tested a treatment for hepatitis C infection that combines chenodeoxycholic acid with bezafibrate.[12]
See also
References
- ^ PMID 12543708.
- ISBN 9780124166875.
- ^ PMID 25210150.
- PMID 1186807.
- PMID 10334993.
- S2CID 195327087.
- PMID 4580472.
- ^ PMID 2672842.
- PMID 6504105.
- PMID 8291509.)
{{cite journal}}
: CS1 maint: numeric names: authors list (link - PMID 20691689.
- ^ Giaconda. "Press release". Archived from the original on 7 April 2014. Retrieved 5 April 2014.